GlioblastomaSipos, Dávid (Avtor) Raposa, Bence (Avtor) Freihat, Omar (Avtor) Simon, Mihály (Avtor) Mekiš, Nejc (Avtor) Cornacchione, Patrizia (Avtor) Kovács, Árpád (Avtor) glioblastomaprognosistreatmentsurvivaloutcomeGlioblastoma is the most aggressive brain cancer and has challenging survival outcomes despite comprehensive treatment strategies. Typical survival for newly diagnosed patients is 12–15 months with a two-year survival rate below 30%. Treatment generally includes surgical resection, radiation, and temozolomide chemotherapy. Key factors impacting prognosis include patient age, molecular markers, and the extent of tumor resection. Younger patients and those with IDH-mutant or MGMT-methylated tumors often fare better. For recurrent cases, median survival drops to about six months, with treatments offering mostly palliative benefits. Innovations like tumor-treating fields (TTFields) provide a modest survival extension. Comprehensive care also requires managing symptoms like seizures and headaches, along with psychological support for patients and caregivers to improve quality of life. Although current therapies have limited efficacy due to glioblastoma’s resistance, ongoing clinical trials and research into targeted and immunotherapies provide hope for improved outcomes in the future. 20252025-01-15 14:03:14Članek v reviji166501UDK: 616-006.04ISSN pri članku: 2072-6694DOI: 10.3390/cancers17010146COBISS_ID: 222491907sl